Am J Surg Pathol

1. ICZKOWSKI KA, De Marzo AM, Agarwal N, Berman DM, et al
   International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate.
   Am J Surg Pathol. 2025;49:e33-e45.
   

   >> Share

   
   

   
   BJU Int

2. HUANG S, Chen DC, Qu L, Papa N, et al
   A meta-analysis of Retzius-sparing and hood-technique robot-assisted radical prostatectomy.
   BJU Int. 2025;136 Suppl 2:S18-S27.
   

   >> Share

   
   
3. RUSH HL, Merrick S, Marshall J, Deighan J, et al
   Preferences between three options for androgen deprivation therapy: a focus group study.
   BJU Int. 2025;136:1037-1047.
   

   >> Share

   
   

   
   BMC Cancer

4. LEE S, Park I, Ahn B, Lim B, et al
   Evaluation of intraductal carcinoma and invasive cribriform carcinoma as predictors of genetic mutations in systemic treatment-naive prostate cancer patients.
   BMC Cancer. 2025;25:1736.
   

   >> Share

   
   

   
   BMC Urol

5. ZHU C, Geng H, Zhang W, Zhou T, et al
   Knowledge associated with attitudes and practice in the management of post-prostatectomy erectile dysfunction: a cross-sectional study.
   BMC Urol. 2025;25:281.
   

   >> Share

   
   
6. GONCHAROV A, Shindyapin V, Popov A, Aslanyan A, et al
   "Robotic-assisted surgical management of a post-brachytherapy rectoprostatic fistula: a case report".
   BMC Urol. 2025;25:278.
   

   >> Share

   
   

   
   Br J Radiol

7. REMBAK-SZYNKIEWICZ J, Hebda A, Mazgaj P, Cortez AJ, et al
   The clinical application of Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR) in histologically confirmed prostate cancer recurrence after radical radiotherapy.
   Br J Radiol. 2025 Nov 10:tqaf273. doi: 10.1093.
   

   >> Share

   
   

   
   Cancer Res

8. JACOBI JJ, Wadosky KM, Jaiswal N, Zhang X, et al
   EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression.
   Cancer Res. 2025 Nov 12. doi: 10.1158/0008-5472.CAN-25-2747.
   

   >> Share

   
   

   
   Eur Urol

9. CHEN F, Sheng X, Wang A, Xu Y, et al
   Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry.
   Eur Urol. 2025 Nov 5:S0302-2838(25)04720-7. doi: 10.1016/j.eururo.2025.09.4161.
   

   >> Share

   
   
10. NG CPY, Light A, Eragamreddy SK, Boaz RJ, et al
    Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway.
    Eur Urol. 2025 Nov 7:S0302-2838(25)04778-5. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    J Clin Oncol

11. KISHAN AU, Valle LF, Wilhalme H, Felix C, et al
    (177)Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.
    J Clin Oncol. 2025 Nov 12:JCO2501553. doi: 10.1200/JCO-25-01553.
    

    >> Share

    
    

    
    J Magn Reson Imaging

12. DENG Y, Liu G, Chen J, He S, et al
    Comparison of 5 T and 3 T Biparametric MRI for Clinically Suspected Prostate Cancer: Image Quality, Lesion Visualization, and Artifacts.
    J Magn Reson Imaging. 2025 Nov 12. doi: 10.1002/jmri.70171.
    

    >> Share

    
    

    
    J Natl Cancer Inst

13. VO JB, Brown DW, Buller ID, Shing JZ, et al
    Associations of self-identified race and ethnicity and genetic ancestry with mortality among cancer survivors.
    J Natl Cancer Inst. 2025;117:2382-2387.
    

    >> Share

    
    

    
    J Nucl Med

14. CERCI JJ, Fanti S, Lobato EE, Kumar R, et al
    (68)Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, International IAEA Study.
    J Nucl Med. 2025 Nov 13:jnumed.125.270537. doi: 10.2967/jnumed.125.270537.
    

    >> Share

    
    

    
    Mod Pathol

15. ZABIHOLLAHY F, Shi K, Wangulu C, Prassas I, et al
    Clinical Grade Interpretable Artificial Intelligence Tool for Automated Detection of Lymph Node Metastasis in Prostate Cancer.
    Mod Pathol. 2025 Nov 10:100934. doi: 10.1016/j.modpat.2025.100934.
    

    >> Share

    
    

    
    Nat Rev Urol

16. ADELEKE S, Galante JR, Wang Y, Azad G, et al
    Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.
    Nat Rev Urol. 2025 Nov 10. doi: 10.1038/s41585-025-01107.
    

    >> Share

    
    
17. CARCELES-CORDON M, Rodriguez-Bravo V, Petrylak DP, Domingo-Domenech J, et al
    20 years of taxane therapy in prostate cancer - the past, present and future.
    Nat Rev Urol. 2025 Nov 10. doi: 10.1038/s41585-025-01104.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

18. ZHANG X, Yang Y, Zou H, Cai D, et al
    Circadian regulator REV-ERBalpha is a master regulator of tumor lineage plasticity and an effective therapeutic target.
    Proc Natl Acad Sci U S A. 2025;122:e2513468122.
    

    >> Share

    
    

    
    Prostate

19. LORENZO-SANCHEZ MV, Gimenez-Bachs JM, Picazo-Martinez MG, Donate-Moreno MJ, et al
    Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer.
    Prostate. 2025 Nov 10. doi: 10.1002/pros.70090.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share